Ontology highlight
ABSTRACT: Background
Preclinical data demonstrate a key role for the epidermal growth factor receptor (EGFR) in the carcinogenesis of cutaneous squamous cell carcinomas (CSCCs). There are, however, limited data on the efficacy of EGFR inhibitors in incurable, recurrent, and/or metastatic CSCC.Objective
To determine the response rate to gefitinib in patients with CSCC not amenable to curative therapy including surgery or radiation.Methods
This was a single-arm phase II study. A total of 40 patients were treated with gefitinib, 250 mg orally daily, until disease progression or intolerable toxicities. The prespecified target response rate of interest was 20%.Results
The overall response rate was 16% (95% confidence interval, 0.06-0.32; 6 partial responses in 37 evaluable
SUBMITTER: William WN
PROVIDER: S-EPMC5685879 | biostudies-literature | 2017 Dec
REPOSITORIES: biostudies-literature